Repligen Co. (NASDAQ:RGEN – Get Free Report) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $185.20.
Several equities analysts have recently issued reports on RGEN shares. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th.
View Our Latest Analysis on Repligen
Hedge Funds Weigh In On Repligen
Repligen Price Performance
Shares of RGEN stock opened at $160.51 on Friday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock’s 50-day simple moving average is $148.36 and its 200-day simple moving average is $144.64.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the company earned $0.23 EPS. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. On average, analysts forecast that Repligen will post 1.54 EPS for the current year.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
- Five stocks we like better than Repligen
- What is Forex and How Does it Work?
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- Best Stocks Under $5.00
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Canada Bond Market Holiday: How to Invest and Trade
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.